Drugs / mDC3/8-KRAS Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03592888 | Nov 2018 → Feb 2024 | pancreatic ductal adenocarcinoma | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mDC3/8-KRAS Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03592888 ↗ |
| Target | KRAS | “A phase 1 clinical vaccine trial targeting KRASMUT was conducted.” PMID 39287991 ↗ Sep 2024 |